Cenicriviroc, a CCR2/CCR5 inhibitor, is being used in clinical trials for the treatment of liver fibrosis in nonalcoholic steatohepatitis patients47. This evidence concerns the gene CCR5 and metabolic dysfunction-associated steatohepatitis.